Please use this identifier to cite or link to this item:
https://hdl.handle.net/11499/10532
Title: | Real-life safety and efficacy of vildagliptin as add-on to metformin in patients with type 2 diabetes in Turkey - GALATA study | Authors: | Ayvaz, G. Keskin, L. Akın, Fulya Dokmetas, H.S. Tasan, E. Ar, I.B. Uren, E. |
Keywords: | DPP-4 HbA1c Real-life Type 2 diabetes Vildagliptin hemoglobin A1c liver enzyme metformin vildagliptin adamantane antidiabetic agent dipeptidyl peptidase IV inhibitor glycosylated hemoglobin nitrile pyrrolidine derivative add on therapy adult Article body mass constipation diarrhea drug efficacy drug safety drug tolerability eye disease female gastrointestinal symptom heart disease human hypoglycemia kidney disease major clinical study male mental disease metabolic disorder middle aged multicenter study nausea non insulin dependent diabetes mellitus peripheral edema skin manifestation Turkey (republic) vascular disease weight reduction analogs and derivatives chemically induced clinical trial cohort analysis Diabetes Mellitus, Type 2 drug combination drug monitoring prospective study treatment outcome Turkey Adamantane Body Mass Index Cohort Studies Dipeptidyl-Peptidase IV Inhibitors Drug Monitoring Drug Therapy, Combination Female Hemoglobin A, Glycosylated Humans Hypoglycemia Hypoglycemic Agents Male Metformin Middle Aged Nitriles Prospective Studies Pyrrolidines Treatment Outcome |
Publisher: | Informa Healthcare | Abstract: | Objective: To evaluate tolerability/safety and the efficacy of the combination of vildagliptin plus metformin in a real-life population of patients with type 2 diabetes mellitus (T2DM). Research design and methods: This multicenter, single-arm, 6 month, observational, prospective cohort study was conducted at 39 centers across Turkey. T2DM patients on vildagliptin and metformin for ?4 weeks were enrolled regardless of their previous antidiabetic therapy. Main outcome measures: Efficacy was evaluated by measuring hemoglobin A1c (HbA1c) levels. Tolerability/safety parameters evaluated included hypoglycemic events, gastrointestinal events, peripheral edema and weight gain. Results: This study enrolled 665 patients with a mean±standard deviation (SD) age of 55.1±10.2 years and female predominance (n=394, 59.2%). Safety was assessed in all enrolled patients. Hypoglycemia was reported in 10 (1.5%) patients (95% confidence interval = 0.8-2.7%). Efficacy was assessed in 289 (43.5%) patients treated for 6±1 months; these patients showed a mean decrease in HbA1c of 0.8% from baseline value of 7.8% (p<0.001). The percentages of patients who achieved HbA1c targets of ?6.5% and ?7.0% were significantly increased, from 10.7% to 33.6% and from 22.1% to 52.6%, respectively (p<0.001 each). The decrease in HbA1c was independent of baseline HbA1c (?8% vs. 8-10% vs. ?10%), age (?65 vs. >65 years) and body mass index (<30 vs. ?30 kg/m2) (p<0.001 each). In total, 136 adverse events (AEs) were observed in 71 (10.7%) patients; 10 (1.5%) patients experienced hypoglycemia and gastrointestinal AEs were most commonly reported (n=29, 4.4%). Conclusions: In a 'real-life' setting, the vildagliptin and metformin combination was associated with significant improvements in reaching target HbA1c levels, even in elderly and obese patients with T2DM. Moreover, vildagliptin and metformin demonstrated a good overall tolerability/safety profile. © 2015 All rights reserved: reproduction in whole or part not permitted. | URI: | https://hdl.handle.net/11499/10532 https://doi.org/10.1185/03007995.2015.1019609 |
ISSN: | 0300-7995 |
Appears in Collections: | PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection Tıp Fakültesi Koleksiyonu WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection |
Show full item record
CORE Recommender
SCOPUSTM
Citations
6
checked on Oct 13, 2024
WEB OF SCIENCETM
Citations
7
checked on Oct 22, 2024
Page view(s)
44
checked on Aug 24, 2024
Google ScholarTM
Check
Altmetric
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.